Lite Strategy Inc LITS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.91
- Day Range
- $0.85–0.92
- 52-Week Range
- $0.69–5.55
- Bid/Ask
- $0.86 / $0.91
- Shares Outstanding
- 31.88M
- Market Cap
- $29.61M
- Volume/Avg
- 198,929 / 358,807
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.litestrategy.com
Valuation
|
Metric
|
LITS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.56 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
LITS
Financial Strength
|
Metric
|
LITS
|
|---|---|
Quick Ratio | 10.11 |
Current Ratio | 11.53 |
Interest Coverage | — |
Quick Ratio
LITS
Profitability
|
Metric
|
LITS
|
|---|---|
Return on Assets (Normalized) | −102.27% |
Return on Equity (Normalized) | −104.29% |
Return on Invested Capital (Normalized) | −105.00% |
Return on Assets
LITS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^YLlP< | LOCK|d$T> | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|mNMWf@ | LOCK|jFCj | $81B | |||
| argenx SE ADR
ARGX
| LOCK|Qbl>L%? | LOCK|$Xd | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!>w%$^PK | LOCK|<BKL | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|z<#XWV^ | LOCK|J% | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>>@l$l | LOCK|Z^<% | $29B | |||
| Incyte Corp
INCY
| LOCK|%lHP>% | LOCK|&rp | $24B | |||
| Moderna Inc
MRNA
| LOCK|&>&b>>W | LOCK|?% | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|b%m#?!P | LOCK|R^& | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|??>f?!B | LOCK|d@ | $17B |
United States